Wedbush upgrades Sarepta Therapeutics, citing overdone selloff and potential upside as FDA could re-approval Elevidys for non ...

On November 25, 2025, Sarepta Therapeutics filed two petitions for inter partes review (“IPR”) challenging Genzyme’s patents relating to ...

This article has been revised and clarified. Pasadena-based biopharma company Arrowhead Pharmaceuticals Inc. had a ...

Analysts are intrested in these 5 stocks: ( ($VRT) ), ( ($AFRM) ), ( ($SRPT) ), ( ($MU) ) and ( ($PEP) ). Here is a breakdown of their recent ...

As previously reported, Wedbush initiated coverage of Sarepta (SRPT) with an Outperform rating and $32 price target The firm sees the early summer ...

WASHINGTON, DC – Dr. Vinay Prasad has been reinstated to a senior position at the Food and Drug Administration, according to an August 9 statement from the Department of Health and Human Services (HHS ...

The firm plans to seek accelerated approval from the FDA next year, while it launches a Phase III trial to support other regulatory applications.

As the FDA unveils a parade of initiatives aimed at accelerating drug development for rare diseases, experts appeal for a ...

Sarepta Therapeutics (SRPT) has quietly staged a sharp rebound over the past month, even though the longer term chart still looks bruised. That mix of momentum and past damage naturally raises ...

Wondering if Sarepta Therapeutics is a beaten down biotech bargain or a value trap? This article will walk through the numbers in plain English so you can decide with confidence. Despite a brutal long ...

Once the exchange agreements close, Sarepta will have $893.4 million in debt due in 2030 following previous refinancing it announced in August.